NCT06677307

A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110

A Phase 1/2a, Single- and Multiple-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KRRO 110 in Healthy Adult Volunteers and in Adult Participants With Alpha-1 Antitrypsin Deficiency (AATD) (REWRITE)

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Korro Bio, Inc. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The purpose of this first-in human (FIH) study is to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple doses of KRRO-110 in both healthy adult participants and in clinically stable patients with Alpha-1 antitrypsin deficiency (AATD).

Conditions

• Alpha-1 Anti-trypsin Deficiency
• AATD

Interventions

Type	Name	Description
DRUG	KRRO-110	KRRO-110 drug product, IV

Timeline

• Start date: 2025-01-13
• Primary completion: 2025-10-31
• Completion: 2025-12-15
• First posted: 2024-11-06
• Last updated: 2026-04-17

Locations

5 sites across 2 countries: Australia, New Zealand